Phase III looms for ProFibrix's new blood clotting drug
This article was originally published in Scrip
Executive Summary
A US multicentre Phase II trial of ProFibrix's Fibrocaps has met all its endpoints. "We plan to initiate a pivotal Phase III trial in H1 2012 and target a BLA filing in 2013," said Jan Öhrström, CEO of the Dutch firm.